ClinicalTrials.gg
Status unknownNCT03496025Updated Dec 19, 2020

Facial Function Reanimation by Electrical Pacing in Unilateral Facial Paralysis.

A Phase 1 interventional study of Electrical muscle stimulation in Facial Nerve Palsy, sponsored by Tampere University Hospital. Status unknown at 1 site in Finland. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-12-19.

Sponsored by Tampere University Hospital · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Sep 2019), so the status shown — last known as Active, not recruiting — may be out of date.

From the registry’s dates

  • Registered 2 years 7 months after the study started (first participant enrolled Aug 2015, registered Mar 2018).
Phase
Phase 1
Study type
Interventional
Enrollment
77
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Purpose of the trial is to study the activations of paralyzed facial muscles in a unilateral facial nerve palsy with a multi-channel electrical stimulator. The principle of the device is to measure muscle activity of the healthy side of the face by surface electromyography (EMG) and to use this information to stimulate the corresponding muscles of the paralyzed side. The ultimate goal is to develop a prosthetic device for persons with a facial nerve palsy.

The trial consists of several different studies. The studies' aims are 1. To study activations of paralyzed facial muscles by the electrical stimulation. 2. To study different stimulation pulse waveforms, frequencies, and electrode placement and their effect on the muscle activations and the tolerability of the stimulation. 3. To study whether a symmetrical movement on the paralyzed side can be achieved with electrical stimulation when compared to the movements of the healthy side. 4. To study tolerability of stimulation-elicited eye blink when watching a film and the effect of the stimulation-induced blink on the eye symptoms, the visual acuity, and the effects of the stimulation on the lacrimal fluid. 5. To develop a method for facial pacing, i.e. measuring the muscle activations on the healthy side of the face and to use this information to stimulate and activate the healthy side of the face.

Forty subjects with a chronic facial nerve palsy are recruited to the studies. Each subject can participate in one or several studies. Another forty subjects with an acute facial nerve palsy are recruited to the study on the tolerability and effect on the eye symptoms. Additionally, altogether ninety healthy volunteers are recruited to the studies in order to gather preliminary information on the tolerability and the effects of the stimulations.

02

Conditions studied

  • Facial Nerve Palsy

Keywords

  • facial nerve palsy
  • facial paralysis
  • functional electrical stimulation
  • facial pacing
03

In context

Bell Palsy

85 studies on the registry are indexed under Bell Palsy; 30 are open to participants now.

This study's enrollment of 77 is above the median of 42 across 70 interventional studies indexed under Bell Palsy.

Browse Bell Palsy studies →

Lead sponsor

Tampere University Hospital is the lead sponsor of 212 studies on the registry; 56 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • a unilateral peripheral facial nerve palsy (patients)
  • willingness to participate (patients, healthy volunteers)

Exclusion criteria

Exclusion Criteria:

  • malignant diseases (a previously treated cancer is not an exclusion criterion)
  • unstable cardiovascular disease
  • severe immune deficiency
  • other severe neurological diseases (causing cognitive or physical impairment)
  • diabetic neuropathy
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
77 participants (actual)

Study arms

  • Experimental
    Electrical stimulation

    Device: Electrical muscle stimulation

Interventions

  • DeviceElectrical muscle stimulation

    The intervention consists of activating paralyzed facial muscles with electrical stimulation.

06

What researchers measure

Primary outcomes

  1. Amplitudee of the movement elicited by electrical stimulation

    The offline video analysis is done to determine the current threshold at which a movement of the target muscle is produced. Possible activations of the other muscles alongside the target muscle are also observed. The amplitude of the movement is analyzed offline from a video recording either visually by the investigators, or measured with a digital ruler. With visual evaluation, the outcome is measured on a rough level, i.e. whether the stimulated movement was larger in amplitude compared to the voluntary movement. With a digital ruler, the results a presented numerically (millimeters). The stimulated activation is compared to the voluntary activation of the muscle. Further, in some sub-studies, the facial activations are evaluated with the Facial Action Coding System.

    Time frame: Immediate

Secondary outcomes

  1. Subjective ratings related to the tolerability of stimulations

    The participants evaluate the experienced discomfort and painfulness of the stimulation with a numeric rating scale (NRS).

    Time frame: Immediate

  2. Subjective ratings related to acceptability of the stimulated movement

    The participants evaluate the naturalness and symmetry and their satisfaction with the stimulation elicited movement with an NRS.

    Time frame: Immediate

  3. Visual acuity

    In substudies concerning the elicitation of eye blink, The visual acuity is measured for both eyes separately with a LogMAR chart before and after the stimulation session.

    Time frame: Immediate

  4. Changes in lacrimal fluid

    In substudies concerning the elicitation of eye blink, a lacrimal fluid sample is collected before and after the stimulation session to investigate the possible effects of the stimulation in its constitution.

    Time frame: Immediate

07

Study locations

1 site
  • Tampere University Hospital
    Tampere, 33521, Finland
08

References and documents

Publications

  • Makela EA, Ilves MK, Venesvirta HM, Lylykangas JK, Rantanen VT, Vehkaoja AT, Verho JA, Lekkala J, Surakka VV, Rautiainen MEP. Effect of pulse waveforms on movement amplitudes and perceived discomfort in electric muscle stimulation in unresolved facial nerve palsy. Biomed Phys Eng Express. 2020 Mar 25;6(3):035013. doi: 10.1088/2057-1976/ab7eea. PubMed 33438658 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2015 to primary completion in Oct 2018, 38 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2018
First posted
Apr 12, 2018
StartActual
Aug 1, 2015
Primary completionActual
Oct 31, 2018
CompletionEst.
May 31, 2021
Last update
Dec 19, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03496025
Collaborators
Tampere University, Tampere University of Technology, Helsinki University Central Hospital
Responsible party
Sponsor
First posted
Apr 12, 2018
Start date
Aug 1, 2015
Primary completion
Oct 31, 2018
Completion
May 31, 2021 (estimated)
Last update
Dec 19, 2020

Study contacts

Markus Rautiainen, MD, PhD
study director · professor, head physician

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion